MoMa Therapeutics
6 articles with MoMa Therapeutics
-
BioSpace Movers & Shakers, May 7
5/7/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
MOMA Therapeutics Appoints Peter Hammerman, M.D., Ph.D., as Chief Scientific Officer
5/3/2021
MOMA Therapeutics, a biopharmaceutical company discovering the next generation of precision medicines by targeting molecular machines that underlie human disease, today announced that Peter Hammerman, M.D., Ph.D., has been appointed as the company’s chief scientific officer.
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
MOMA Therapeutics and Eli Lilly are both experiencing significant changes in their leadership roster, with one Takeda alum taking the helm at MOMA and an R&D chief at Lilly shooting toward the exit door.
-
MOMA Therapeutics Appoints Asit Parikh, M.D., Ph.D. as President and Chief Executive Officer
2/1/2021
MOMA Therapeutics, a biopharmaceutical company discovering the next generation of precision medicines by targeting molecular machines that underlie human disease, today announced that Asit Parikh, M.D., Ph.D., has been appointed as the company’s president and chief executive officer, effective April 5, 2021.
-
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.